Partnering to provide breakthrough treatments to patients around the world suffering from rare genetic diseases
Over the years, BioMarin has grown its business and product pipeline independently as well as through strategic partnerships with individuals, research institutions and companies that offer complementary vision and expertise. Through partnerships with research scientists, universities and biopharmaceutical companies, BioMarin is finding new ways to better meet the needs of patients around the world suffering from rare genetic diseases.
The following are some of our current partners companies.
For the development and commercialization of Aldurazyme® (laronidase) for MPS I
For the development and ex-U.S./ex-Japan/ex-Canada commercialization (pending regulatory approvals) of BioMarin's KUVAN® (sapropterin dihydrochloride) Tablets for Oral Use and Powder for Oral Solution and 6R-BH4 for other indications